What is the recommended antibiotic regimen for acute bacterial rhinosinusitis, including first‑line therapy, alternatives for severe penicillin allergy, dosing, and duration?

Antibiotic Management of Acute Bacterial Rhinosinusitis

Amoxicillin-clavulanate 875 mg/125 mg twice daily for 5–10 days is the preferred first-line antibiotic for adults with confirmed acute bacterial rhinosinusitis, providing 90–92% predicted clinical efficacy against the major pathogens. 1

Diagnostic Criteria Before Prescribing Antibiotics

You must confirm acute bacterial rhinosinusitis (ABRS) by identifying at least one of three specific clinical patterns before initiating antibiotics:

• Persistent symptoms ≥10 days without improvement: purulent nasal discharge plus either nasal obstruction/congestion or facial pain/pressure/fullness lasting ≥10 days. This is the most common presentation. 1, 2

• Severe symptoms ≥3–4 consecutive days at illness onset: high fever ≥39°C (102.2°F) plus purulent nasal discharge plus facial pain/pressure. 1, 2

• "Double sickening": initial improvement from a viral upper respiratory infection (URI) for 5–6 days, then worsening with new-onset fever, headache, or increased purulent nasal discharge within 10 days. 1, 2

Critical context: Approximately 98–99.5% of acute rhinosinusitis episodes are viral and resolve spontaneously within 7–10 days without antibiotics. 1, 3, 4 Do not prescribe antibiotics for symptoms lasting <10 days unless the severe pattern (fever ≥39°C with purulent discharge for ≥3 consecutive days) is present. 1, 3

First-Line Antibiotic Regimen (No Penicillin Allergy)

• Amoxicillin-clavulanate 875 mg/125 mg orally twice daily for 5–10 days (or until symptom-free for 7 consecutive days, typically 10–14 days total). 1, 3

• Rationale: The clavulanate component is essential because 30–40% of Haemophilus influenzae and 90–100% of Moraxella catarrhalis produce β-lactamase, rendering plain amoxicillin ineffective against these organisms. 1

• Shorter courses (5–7 days) provide comparable efficacy with fewer adverse effects and are increasingly recommended. 1, 5

High-Dose Regimen for Specific Risk Factors

Use high-dose amoxicillin-clavulanate 2 g/125 mg twice daily when any of the following risk factors are present:

• Recent antibiotic use within the past 4–6 weeks 1, 2
• Age >65 years 1
• Daycare attendance or close contact with daycare children 1
• Moderate-to-severe symptoms 1
• Comorbidities (diabetes, chronic cardiac/hepatic/renal disease) 1
• Immunocompromised state 1

Alternatives for Penicillin Allergy

Non-Severe (Non-Type I) Penicillin Allergy

• Second- or third-generation cephalosporins for 10 days: cefuroxime-axetil, cefpodoxime-proxetil, cefdinir, or cefprozil. 1

• Cross-reactivity with penicillins is negligible (<1%), making these agents safe for patients with mild rash or delayed reactions. 1

Severe (Type I/Anaphylactic) Penicillin Allergy

• Levofloxacin 500 mg once daily for 10–14 days or Moxifloxacin 400 mg once daily for 10 days. 1

• Both achieve 90–92% predicted clinical efficacy against multidrug-resistant Streptococcus pneumoniae and β-lactamase-producing organisms. 1

• Reserve fluoroquinolones for severe allergy or documented treatment failure to limit resistance development. 1

Suboptimal Alternative

• Doxycycline 100 mg once daily for 10 days offers lower efficacy (77–81%) with a 20–25% bacteriologic failure rate due to limited H. influenzae coverage. 1

• Use only when cephalosporins and fluoroquinolones are contraindicated (e.g., pregnancy, tendon disorders, QT-prolongation risk). 1

• Contraindicated in children <8 years due to tooth enamel discoloration risk. 1

Antibiotics to Avoid

• Macrolides (azithromycin, clarithromycin): 20–25% resistance rates in S. pneumoniae and H. influenzae. The American Academy of Pediatrics explicitly contraindicates azithromycin for ABRS. 1, 6

• Trimethoprim-sulfamethoxazole: ≈50% resistance in S. pneumoniae and ≈27% in H. influenzae. 1

• First-generation cephalosporins (cephalexin, cefadroxil): inadequate because ≈50% of H. influenzae strains produce β-lactamase. 1

Watchful Waiting Strategy

• For uncomplicated ABRS with reliable follow-up, initial observation without antibiotics is appropriate. 1, 3, 7

• Initiate antibiotics only if there is no improvement by day 7 or if symptoms worsen at any time. 1, 3

• The number needed to treat (NNT) with antibiotics is 10–15 to achieve one additional cure compared with placebo, reflecting the high spontaneous recovery rate. 1, 8

Essential Adjunctive Therapies (Add to All Patients)

• Intranasal corticosteroids (mometasone, fluticasone, or budesonide) twice daily significantly reduce mucosal inflammation and accelerate symptom resolution. This recommendation is supported by strong evidence from multiple randomized controlled trials. 1, 3, 7

• Saline nasal irrigation performed 2–3 times daily provides symptomatic relief and aids mucus clearance. 1, 3, 4

• Analgesics (acetaminophen or ibuprofen) for pain and fever control. 1, 3

• Decongestants (oral or topical) may be used; limit topical agents to ≤3 days to avoid rebound congestion. 1, 3, 9

Monitoring and Reassessment Protocol

Early Reassessment (Days 3–5)

• Reassess at 3–5 days of initial therapy. 1, 3

• Persistent purulent nasal discharge, unchanged facial pain/pressure, or worsening symptoms constitute treatment failure and warrant immediate switch to second-line therapy. 1

• Do not extend the initial antibiotic beyond 3–5 days without improvement; early discontinuation prevents unnecessary drug exposure and bacterial proliferation. 1

Day 7 Reassessment

• Persistent or worsening symptoms require: (1) confirmation of ABRS diagnosis, (2) exclusion of complications (orbital cellulitis, meningitis, intracranial abscess), (3) imaging (CT) only if complications are suspected, and (4) referral to otolaryngology. 1, 3

Expected Timeline of Recovery

• Noticeable improvement within 3–5 days of appropriate antibiotic therapy (reduction in fever, facial pain, and purulent drainage). 1, 3

• Complete resolution by 10–14 days or when symptom-free for 7 consecutive days. 1, 3

• Only 30–41% of patients show improvement by days 3–5; zero improvement at this stage indicates likely treatment failure. 1

Second-Line Therapy After Treatment Failure

Preferred Second-Line Regimens

• Levofloxacin 500 mg once daily for 10–14 days or Moxifloxacin 400 mg once daily for 10 days. 1

• Fluoroquinolones are effective after amoxicillin-clavulanate failure because they retain activity against penicillin-resistant and multidrug-resistant S. pneumoniae while covering β-lactamase-producing H. influenzae and M. catarrhalis. 1

Alternative Second-Line Options

• High-dose amoxicillin-clavulanate 2 g/125 mg twice daily for 10 days enhances coverage of drug-resistant S. pneumoniae after standard-dose failure. 1

• Third-generation oral cephalosporins (cefpodoxime, cefdinir) for 10 days provide superior activity against H. influenzae but have limited efficacy against drug-resistant S. pneumoniae. 1

Referral to Otolaryngology

Refer immediately for any of the following:

• No improvement after 7 days of appropriate second-line antibiotic therapy. 1

• Worsening symptoms at any point (increasing facial pain, fever, purulent drainage). 1

• Signs of complications: severe headache, visual changes, periorbital swelling/erythema, proptosis, diplopia, altered mental status, or cranial nerve deficits. 1, 3

• Recurrent sinusitis (≥3 episodes per year) requiring evaluation for underlying allergic rhinitis, immunodeficiency, or anatomic abnormalities. 1, 3, 7

Common Pitfalls to Avoid

• Do not prescribe antibiotics for symptoms <10 days unless severe features (fever ≥39°C with purulent discharge for ≥3 consecutive days) are present. 1, 3

• Avoid routine imaging (X-ray or CT) for uncomplicated ABRS; up to 87% of viral URIs show sinus abnormalities on imaging, leading to unnecessary interventions. 1

• Ensure adequate treatment duration (≥5 days for adults, ≥10 days for children) to prevent relapse. 1, 5

• Gastrointestinal adverse effects with amoxicillin-clavulanate are common: diarrhea in 40–43% of patients, severe diarrhea in 7–8%. 1, 3

• Do not use fluoroquinolones as first-line therapy in patients without documented β-lactam allergy to limit resistance development. 1